Taysha Gene Therapies (TSHA) executive compensation, 2026 proxy

Sean Nolan, Chief Executive Officer and Director, was paid $4.1M in 2025, down 13% from $4.7M the year before.

Filed
April 22, 2026
Annual meeting
June 1, 2026
Pay year
2025
Named executives
3
CEO total pay
$4.1M-13% vs prior year
CEO pay in equity
71%$2.9M in awards
CEO Target Bonus
60%Percentage of annual base salary
Corporate Goals Attainment
140%Non-equity incentive payout factor

How Nolan was paid

$4.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary16%Stock awards40%Option awards31%Non-equity incentive13%All other compensation0%

Named executive officers

ExecutiveTotal
Sean NolanChief Executive Officer and Director$4,099,065
Kamran AlamChief Financial Officer$2,146,964
Sukumar Nagendran, M.D.President and Head of Research and Development and Director$2,092,890

What changed and why

  • $4.1MChief executive officer total compensation decreased to $4,099,065 for the fiscal year.
  • $646KAnnual base salaries were established at $645,840 for the chief executive officer.
  • 140%Corporate goals achievement percentage for the annual non-equity incentive was determined to be 140%.
  • Equity-based incentive awards were granted under the 2020 Stock Incentive Plan.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.